Literature DB >> 12163376

Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric.

Samir Kumar-Singh1, Patrick Cras, Rong Wang, John M Kros, Johan van Swieten, Ursula Lübke, Chantal Ceuterick, Sally Serneels, Krist'l Vennekens, Jean-Pierre Timmermans, Eric Van Marck, Jean-Jacques Martin, Cornelia M van Duijn, Christine Van Broeckhoven.   

Abstract

Alzheimer's disease (AD) is characterized by deposition of beta-amyloid (Abeta) in diffuse and senile plaques, and variably in vessels. Mutations in the Abeta-encoding region of the amyloid precursor protein (APP) gene are frequently associated with very severe forms of vascular Abeta deposition, sometimes also accompanied by AD pathology. We earlier described a Flemish APP (A692G) mutation causing a form of early-onset AD with a prominent cerebral amyloid angiopathy and unusually large senile plaque cores. The pathogenic basis of Flemish AD is unknown. By image and mass spectrometric Abeta analyses, we demonstrated that in contrast to other familial AD cases with predominant brain Abeta42, Flemish AD patients predominantly deposit Abeta40. On serial histological section analysis we further showed that the neuritic senile plaques in APP692 brains were centered on vessels. Of a total of 2400 senile plaque cores studied from various brain regions from three patients, 68% enclosed a vessel, whereas the remainder were associated with vascular walls. These observations were confirmed by electron microscopy coupled with examination of serial semi-thin plastic sections, as well as three-dimensional observations by confocal microscopy. Diffuse plaques did not associate with vessels, or with neuritic or inflammatory pathology. Together with earlier in vitro data on APP692, our analyses suggest that the altered biological properties of the Flemish APP and Abeta facilitate progressive Abeta deposition in vascular walls that in addition to causing strokes, initiates formation of dense-core senile plaques in the Flemish variant of AD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163376      PMCID: PMC1850756          DOI: 10.1016/S0002-9440(10)64207-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  75 in total

1.  Toxicity of pyroglutaminated amyloid beta-peptides 3(pE)-40 and -42 is similar to that of A beta1-40 and -42.

Authors:  T L Tekirian; A Y Yang; C Glabe; J W Geddes
Journal:  J Neurochem       Date:  1999-10       Impact factor: 5.372

Review 2.  Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Authors:  G G Glenner
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

3.  Congophilic angiopathy in the pathogenesis of Alzheimer's degeneration.

Authors:  G G Glenner; J H Henry; S Fujihara
Journal:  Ann Pathol       Date:  1981       Impact factor: 0.407

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

Review 5.  Critical threshold cerebral hypoperfusion causes Alzheimer's disease?

Authors:  J C de la Torre
Journal:  Acta Neuropathol       Date:  1999-07       Impact factor: 17.088

Review 6.  Hypothesis: amyloid beta-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease.

Authors:  A J Larner
Journal:  Neurobiol Aging       Date:  1999 Jan-Feb       Impact factor: 4.673

7.  The relationship between senile plaques and cerebral blood vessels in Alzheimer's disease and senile dementia. Morphological mechanism of senile plaque production.

Authors:  T Miyakawa; A Shimoji; R Kuramoto; Y Higuchi
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1982-08

8.  An immunohistochemical study of beta-protein in Alzheimer-type dementia brains.

Authors:  H Arai; N Sagi; I Noguchi; S Haga; T Ishii; Y Makino; K Kosaka
Journal:  J Neurol       Date:  1989-05       Impact factor: 4.849

9.  beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.

Authors:  A E Roher; J D Lowenson; S Clarke; A S Woods; R J Cotter; E Gowing; M J Ball
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

10.  Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer's amyloid beta/A4 peptide.

Authors:  A Clements; D M Walsh; C H Williams; D Allsop
Journal:  Neurosci Lett       Date:  1993-10-14       Impact factor: 3.046

View more
  29 in total

Review 1.  Genetic animal models of cerebral vasculopathies.

Authors:  Jeong Hyun Lee; Brian J Bacskai; Cenk Ayata
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

2.  Fusogenic Alzheimer's peptide fragment Abeta (29-42) in interaction with lipid bilayers: secondary structure, dynamics, and specific interaction with phosphatidyl ethanolamine polar heads as revealed by solid-state NMR.

Authors:  Stéphanie Ravault; Olivier Soubias; Olivier Saurel; Annick Thomas; Robert Brasseur; Alain Milon
Journal:  Protein Sci       Date:  2005-05       Impact factor: 6.725

3.  Antibody elution method for multiple immunohistochemistry on primary antibodies raised in the same species and of the same subtype.

Authors:  Daniel Pirici; Laurentiu Mogoanta; Samir Kumar-Singh; Ionica Pirici; Claudiu Margaritescu; Cristina Simionescu; Radu Stanescu
Journal:  J Histochem Cytochem       Date:  2009-02-16       Impact factor: 2.479

Review 4.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

5.  Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain.

Authors:  Atsushi Aoyagi; Carlo Condello; Jan Stöhr; Weizhou Yue; Brianna M Rivera; Joanne C Lee; Amanda L Woerman; Glenda Halliday; Sjoerd van Duinen; Martin Ingelsson; Lars Lannfelt; Caroline Graff; Thomas D Bird; C Dirk Keene; William W Seeley; William F DeGrado; Stanley B Prusiner
Journal:  Sci Transl Med       Date:  2019-05-01       Impact factor: 17.956

6.  Registration of whole immunohistochemical slide images: an efficient way to characterize biomarker colocalization.

Authors:  Xavier Moles Lopez; Paul Barbot; Yves-Rémi Van Eycke; Laurine Verset; Anne-Laure Trépant; Lionel Larbanoix; Isabelle Salmon; Christine Decaestecker
Journal:  J Am Med Inform Assoc       Date:  2014-08-14       Impact factor: 4.497

7.  Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls.

Authors:  Samir Kumar-Singh; Daniel Pirici; Eileen McGowan; Sally Serneels; Chantal Ceuterick; John Hardy; Karen Duff; Dennis Dickson; Christine Van Broeckhoven
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

8.  Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-β proteins in the cerebral vasculature.

Authors:  Edward K Agyare; Sarah R Leonard; Geoffry L Curran; Caroline C Yu; Val J Lowe; Anant K Paravastu; Joseph F Poduslo; Karunya K Kandimalla
Journal:  Mol Pharm       Date:  2013-03-05       Impact factor: 4.939

9.  Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.

Authors:  R J S Viana; A F Nunes; R E Castro; R M Ramalho; J Meyerson; S Fossati; J Ghiso; A Rostagno; C M P Rodrigues
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

Review 10.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.